Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, January 10th. The brokerage presently has a $105.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 6.75% from the stock’s previous close.
According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
Other equities research analysts have also issued reports about the company. HC Wainwright raised their target price on Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, December 6th. Roth Capital set a $82.00 target price on Madrigal Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. Evercore ISI lifted their price objective on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, December 7th. Finally, JMP Securities lifted their price objective on Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday, December 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $129.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.11. analysts predict that Madrigal Pharmaceuticals will post -2.57 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. VHCP Management II LLC purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $1,349,000. JPMorgan Chase & Co. purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $325,000. SG Americas Securities LLC purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $100,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth about $353,000. Finally, Bank of New York Mellon Corp increased its holdings in Madrigal Pharmaceuticals by 17.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 1,963 shares during the last quarter. 19.10% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Madrigal Pharmaceuticals (NASDAQ:MDGL) Rating Increased to Buy at Zacks Investment Research” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/madrigal-pharmaceuticals-mdgl-rating-increased-to-buy-at-zacks-investment-research/1821860.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.